I think we are seeing a lot more strategic alliances and partnering of early stage companies simply because it's so expensive to put a drug through clinical trials and a lot of companies when evaluating their opportunities, as I mentioned earlier, realize that you know, you really have to consider w...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
